In March, the RESILIENCE project passed the halfway point of its recruitment process, with more than 300 people participating in this clinical trial, which aims to reduce the incidence of heart failure in cancer survivors.
Patients are distributed among the 22 hospitals in the six countries participating in this multinational project funded by the European Commission, with Spain leading the recruitment process, followed by Germany, Portugal, Denmark, France, and the Netherlands.
Since February, the spectrum of patients eligible to participate in the RESILIENCE trial has been expanded to include not only people with lymphoma but also those with breast cancer receiving anthracycline treatment who meet the criteria assessed by their oncologists.
